The Scent of Love is in the Air(way): a Potential Drug Target for Sleep Apnea?

Overview

Journal Sleep

Publisher Oxford University Press

Specialty Psychiatry

Date 2023 Jan 31

PMID 36719095

Authors

Amal M Osman

Thomas J Altree

Danny J Eckert

Affiliations

Soon will be listed here.

References

Buemann B, Uvnas-Moberg K . Oxytocin may have a therapeutical potential against cardiovascular disease. Possible pharmaceutical and behavioral approaches. Med Hypotheses. 2020; 138:109597. DOI: 10.1016/j.mehy.2020.109597. View

Marazziti D, Diep P, Carter S, Carbone M . Oxytocin: An Old Hormone, a Novel Psychotropic Drug and its Possible Use in Treating Psychiatric Disorders. Curr Med Chem. 2022; 29(35):5615-5687. DOI: 10.2174/0929867329666220727120646. View

Edwards B, Sands S, Eckert D, White D, Butler J, Owens R . Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea. J Physiol. 2012; 590(5):1199-211. PMC: 3381825. DOI: 10.1113/jphysiol.2011.223925. View

Berger S, Pho H, Fleury-Curado T, Bevans-Fonti S, Younas H, Shin M . Intranasal Leptin Relieves Sleep-disordered Breathing in Mice with Diet-induced Obesity. Am J Respir Crit Care Med. 2018; 199(6):773-783. PMC: 6423095. DOI: 10.1164/rccm.201805-0879OC. View

Nawijn L, van Zuiden M, Koch S, Frijling J, Veltman D, Olff M . Intranasal oxytocin increases neural responses to social reward in post-traumatic stress disorder. Soc Cogn Affect Neurosci. 2016; 12(2):212-223. PMC: 5390752. DOI: 10.1093/scan/nsw123. View

Horner R, Grace K, Wellman A . A resource of potential drug targets and strategic decision-making for obstructive sleep apnoea pharmacotherapy. Respirology. 2017; 22(5):861-873. PMC: 5515492. DOI: 10.1111/resp.13079. View

Quintana D, Lischke A, Grace S, Scheele D, Ma Y, Becker B . Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol Psychiatry. 2020; 26(1):80-91. PMC: 7815514. DOI: 10.1038/s41380-020-00864-7. View

Osman A, Mukherjee S, Altree T, Delbeck M, Gehring D, Hahn M . Topical Potassium Channel Blockage Improves Pharyngeal Collapsibility: A Translational, Placebo-Controlled Trial. Chest. 2022; 163(4):953-965. DOI: 10.1016/j.chest.2022.11.024. View

Raymond J, Rehn S, Hoyos C, Bowen M . The influence of oxytocin-based interventions on sleep-wake and sleep-related behaviour and neurobiology: A systematic review of preclinical and clinical studies. Neurosci Biobehav Rev. 2021; 131:1005-1026. DOI: 10.1016/j.neubiorev.2021.10.016. View

10.

Liu W, Ladha R, Liu H, Horner R . Thyrotropin-releasing hormone analog as a stable upper airway-preferring respiratory stimulant with arousal properties. J Appl Physiol (1985). 2022; 133(5):1067-1080. PMC: 9602822. DOI: 10.1152/japplphysiol.00414.2022. View

11.

Messineo L, Taranto-Montemurro L, Calianese N, Gell L, Azarbarzin A, Labarca G . Atomoxetine and fesoterodine combination improves obstructive sleep apnoea severity in patients with milder upper airway collapsibility. Respirology. 2022; 27(11):975-982. PMC: 10041976. DOI: 10.1111/resp.14326. View

12.

Horner R, Hughes S, Malhotra A . State-dependent and reflex drives to the upper airway: basic physiology with clinical implications. J Appl Physiol (1985). 2013; 116(3):325-36. PMC: 3921354. DOI: 10.1152/japplphysiol.00531.2013. View

13.

Jain V, Marbach J, Kimbro S, Andrade D, Jain A, Capozzi E . Benefits of oxytocin administration in obstructive sleep apnea. Am J Physiol Lung Cell Mol Physiol. 2017; 313(5):L825-L833. DOI: 10.1152/ajplung.00206.2017. View

14.

Wirth K, Steinmeyer K, Ruetten H . Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs. Sleep. 2013; 36(5):699-708. PMC: 3624824. DOI: 10.5665/sleep.2630. View

15.

Lim R, Messineo L, Grunstein R, Carberry J, Eckert D . The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double-blind, placebo-controlled, randomised crossover trial. J Physiol. 2021; 599(17):4183-4195. DOI: 10.1113/JP281912. View

16.

Mack S, Wu M, Kc P, Haxhiu M . Stimulation of the hypothalamic paraventricular nucleus modulates cardiorespiratory responses via oxytocinergic innervation of neurons in pre-Botzinger complex. J Appl Physiol (1985). 2006; 102(1):189-99. PMC: 1781418. DOI: 10.1152/japplphysiol.00522.2006. View

17.

Chen T, Chung C, Chang H, Kao Y, Chang S, Kuo T . Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea. Sci Rep. 2021; 11(1):12526. PMC: 8206122. DOI: 10.1038/s41598-021-91988-5. View

18.

Taranto-Montemurro L, Messineo L, Sands S, Azarbarzin A, Marques M, Edwards B . The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial. Am J Respir Crit Care Med. 2018; 199(10):1267-1276. PMC: 6519859. DOI: 10.1164/rccm.201808-1493OC. View

19.

Mezzanotte W, Tangel D, White D . Waking genioglossal electromyogram in sleep apnea patients versus normal controls (a neuromuscular compensatory mechanism). J Clin Invest. 1992; 89(5):1571-9. PMC: 443031. DOI: 10.1172/JCI115751. View

20.

Perger E, Taranto Montemurro L, Rosa D, Vicini S, Marconi M, Zanotti L . Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial. Chest. 2021; 161(1):237-247. PMC: 10835052. DOI: 10.1016/j.chest.2021.08.080. View